Literature DB >> 9697082

A note on sample size determination for bioequivalence studies with high-order crossover designs.

K W Chen1, S C Chow, G Li.   

Abstract

Similar to Liu and Chow, approximate formulas for sample size determination are derived based on Schuirmann's two one-sided tests procedure for bioequivalence studies for the additive and the multiplicative models under various higher order crossover designs for comparing two formulations of a drug product. The higher order crossover designs under study include Balaam's design, the two-sequence dual design, and two four-period designs (with two and four sequences), which are commonly used for assessment of bioequivalence between formulations. The derived formulas are simple enough to be carried out with a pocket calculator. The number of subjects required for each of the four higher order designs are tabulated for selected powers and various parameter values.

Mesh:

Year:  1997        PMID: 9697082     DOI: 10.1023/a:1025738019069

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  7 in total

1.  Sample size determination for bioequivalence assessment using a multiplicative model.

Authors:  D Hauschke; V W Steinijans; E Diletti; M Burke
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

2.  Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43.

Authors:  E Diletti; D Hauschke; V W Steinijans
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1992-08

3.  Effect of changing the bioequivalence range from (0.80, 1.20) to (0.80, 1.25) on the power and sample size.

Authors:  V W Steinijans; W W Hauck; E Diletti; D Hauschke; S Anderson
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1992-12

4.  Sample size determination for bioequivalence assessment by means of confidence intervals.

Authors:  E Diletti; D Hauschke; V W Steinijans
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1991-01

5.  Sample size determination for the two one-sided tests procedure in bioequivalence.

Authors:  J P Liu; S C Chow
Journal:  J Pharmacokinet Biopharm       Date:  1992-02

Review 6.  On assessment of bioequivalence under a higher-order crossover design.

Authors:  S C Chow; J P Liu
Journal:  J Biopharm Stat       Date:  1992       Impact factor: 1.051

7.  A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.

Authors:  D J Schuirmann
Journal:  J Pharmacokinet Biopharm       Date:  1987-12
  7 in total
  6 in total

1.  On sample size calculation in bioequivalence trials.

Authors:  S C Chow; H Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

2.  Design and Analysis of Biosimilar Switching Studies.

Authors:  Shein-Chung Chow; Sang Joon Lee
Journal:  Pharmaceut Med       Date:  2019-10

3.  Innovative Design and Analysis for PK/PD Biosimilar Bridging Studies with Multiple References.

Authors:  Fuyu Song; Xin Zheng; Yujia Wang; Shein-Chung Chow; Hongqiang Sun
Journal:  AAPS J       Date:  2021-11-30       Impact factor: 4.009

4.  Bioavailability and Bioequivalence in Drug Development.

Authors:  Shein-Chung Chow
Journal:  Wiley Interdiscip Rev Comput Stat       Date:  2014

5.  Evaluating the Effects of Heat-Clearing Traditional Chinese Medicine in Stable Bronchiectasis by a Series of N-of-1 Trials.

Authors:  Suna Zi; Haiyin Huang; Peilan Yang; Minhua Xu; Yingen Wu; Zhenwei Wang; Fei Ge; Xinlin Chen
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-17       Impact factor: 2.629

6.  Investigation into the Individualized Treatment of Traditional Chinese Medicine through a Series of N-of-1 Trials.

Authors:  Haiyin Huang; Peilan Yang; Jie Wang; Yingen Wu; Suna Zi; Jie Tang; Zhenwei Wang; Ying Ma; Yuqing Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2018-02-07       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.